Amdocs Limited

The stock is still in a long-term downtrend, trading well below its 200-day moving average after a steep reset from the 52-week high. The recent bounce off the low-50s keeps it in a repair phase, but the broader regime remains below trend rather than in a confirmed recovery.

Street sentiment is constructive but cautious: consensus sits at Buy with a $81.5 target, well above the current share price. Recent changes lean softer, with Stifel cutting to $71, Barclays to $92, and CFRA moving to Sell, even as KeyBanc initiated at Sector Weight.

The company has a strong beat pattern, going 6 of the last 7 quarters, including modest beats of 1.1% and 2.8% in the last two reports. Next-quarter EPS is estimated at 1.65, so shareholders should watch whether margin discipline keeps the streak intact after the recent earnings growth decline.

The pattern is mixed but not aggressively bullish: one discretionary sale from Matthew E. Smith and no discretionary buys. Most other filings are awards or zero-share entries, which read as routine compensation activity rather than a clear trading signal.

Profitability remains solid, with a 37.8% gross margin, 16.49% operating margin, and 11.81% net margin. Revenue grew 3.9% year over year, while EPS growth was -11.6%, so the setup favors steady cash generation more than rapid acceleration.

Amdocs sits in the IT services/software infrastructure lane with a premium cash profile and lower beta than many software peers. The stock screens at 7.41x earnings, a discount to the sector’s growth names, which leaves valuation support if execution stays stable.